Immune activation and HIV persistence: implications for curative approaches to HIV infection
Summary Despite complete or near‐complete suppression of human immunodeficiency virus (HIV) replication with combination antiretroviral therapy, both HIV and chronic inflammation/immune dysfunction persist indefinitely. Untangling the association between the virus and the host immune environment dur...
Saved in:
Published in | Immunological reviews Vol. 254; no. 1; pp. 326 - 342 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.07.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
Despite complete or near‐complete suppression of human immunodeficiency virus (HIV) replication with combination antiretroviral therapy, both HIV and chronic inflammation/immune dysfunction persist indefinitely. Untangling the association between the virus and the host immune environment during therapy might lead to novel interventions aimed at either curing the infection or preventing the development of inflammation‐associated end‐organ disease. Chronic inflammation and immune dysfunction might lead to HIV persistence by causing virus production, generating new target cells, enabling infecting of activated and resting target cells, altering the migration patterns of susceptible target cells, increasing the proliferation of infected cells, and preventing normal HIV‐specific clearance mechanisms from function. Chronic HIV production or replication might contribute to persistent inflammation and immune dysfunction. The rapidly evolving data on these issues strongly suggest that a vicious cycle might exist in which HIV persistence causes inflammation that in turn contributes to HIV persistence. |
---|---|
Bibliography: | istex:B5F6DFB19C1B86D97767FBF95C89C8B911E5000D ArticleID:IMR12065 National Institute of Allergy and Infectious Diseases - No. R01 AI087145; No. K24 AI069994 American Foundation for AIDS Research Intramural Program of the National Institute of Allergy and Infectious Diseases ark:/67375/WNG-9JB10F5F-4 Delaney AIDS Research Enterprise - No. U19AI096109 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
ISSN: | 0105-2896 1600-065X 1600-065X |
DOI: | 10.1111/imr.12065 |